15,000% in 5 years! Small-cap multibagger defence stock in focus after ₹150 crore order book update
'NIBE Limited is pleased to announce the receipt of a significant export Purchase Order valued at $17.52 million (approximately ₹ 150.62 crores) from a globally renowned leading technology-based company in Israel,' said the company in the BSE filing.
As per the filing data, the company will manufacture and supply Universal Rocket Launchers, which are capable of reaching up to 300 kilometres and export to the global market.
'The Universal Rocket Launcher is among the most advanced in its class and is designed to outperform currently available global alternatives. This order not only marks a major step forward in NIBE Limited's international expansion but also strengthens India's strategic position in the field of modern warfare systems,' said the company in the BSE filing.
The company also claimed that the manufacturing of the high-tech 'Universal Rocket Launcher' will be the first time it will be produced in India for the global market.
Nibe shares closed 0.50 per cent higher at ₹ 1,525.60 after Friday's market session, compared to ₹ 1,517.95 at the previous stock market close. The company announced the order book update on Saturday, 24 May 2025.
The defence sector stock has given investors more than 15,300 per cent returns in the last five years and 1.96 per cent in the last one-year period. However, on a year-to-date (YTD) basis, the shares have lost 8.69 per cent in 2025.
The stock is trading 7.7 per cent higher in the last one-month period. Nibe shares hit their 52-week high level at ₹ 2,245.40 on 7 August 2024, while the 52-week low levels were at ₹ 753.05 on 19 March 2025, according to the data collected from the BSE website.
The company's market capitalisation (M-Cap) was at ₹ 2,181.08 crore as of the stock market close on Friday, 23 May 2025.
Read all stories by Anubhav Mukherjee
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
22 minutes ago
- India Today
Slamming 50% Trump tariffs, farmer leader Chaduni urges ban on US firms in India
Haryana farmer leader Gurnam Singh Chaduni has called for a complete ban on American companies operating in India after US President Donald Trump announced steep tariffs on Indian week, Trump signed an Executive Order imposing an additional 25% duty on Indian imports — on top of an earlier 25% hike — citing India's continued purchase of Russian oil. The combined 50% tariff will take effect from August to the move, Bharatiya Kisan Union (Chaduni) chief Gurnam Singh Chaduni said India must "hit back in a similar manner" by targeting US companies. "The US has imposed heavy tariffs on India and India must hit back in a similar way and ban American companies operating on Indian soil," Chaduni told India Today farmer leader argued that many American businesses in India, especially large fast-food and retail chains, earn substantial profits and repatriate them to the US."Why are we allowing this when the US is imposing tariffs on us? We must give a similar reply and ban all these companies," he said. "You travel on highways and one can spot the big food giants of the US spreading their business all over. This must stop," Chaduni farmer leader, who played a prominent role in the 2022 anti-farm laws protests, said the government must take a firm stand to deter future trade pressure from Washington."We cannot allow anyone to dictate things to us like this. If we don't take a stand now, America will continue to do this in the future too and threaten us regularly. The US-based companies should immediately be banned and not allowed to mint money," he demand also comes against the backdrop of a long-standing flashpoint in India–US trade of the contentious issues has been the proposed entry of US companies into India's dairy and agriculture sectors — a move New Delhi has consistently resisted, citing potential threats to farmers' livelihoods and to the country's self-reliance in these key Washington escalating trade tensions through higher tariffs, Chaduni's call to ban US businesses signals growing pressure on the Indian government to respond with stronger retaliatory measures.- EndsMust Watch
India Today
22 minutes ago
- India Today
Kanpur leather industry hit by US tariff hike, Rs 2,000 crore exports stalled
Kanpur's leather industry, a major export hub, is staring at a severe crisis after the United States sharply increased import duties on Indian leather goods to 60%—double the rate imposed on China and far higher than Pakistan (19%) and Bangladesh (20%). Exporters fear the move could wipe out nearly all of Kanpur's annual Rs 2,000 crore leather exports to the SAY BUYERS BACKING OUTJafar Iqbal, a Kanpur-based exporter and factory owner, said shipments have been halted as American buyers withdraw from contracts. 'In May, when tariffs were 10%, we agreed to bear half the cost to retain orders. Now, with the new rates, neither side can afford it. Five of our containers are ready, but we don't know what to do,' he told India Today BLOW FOR THE INDUSTRYNaiyar Jamal, another exporter, said the sector was already struggling under environmental regulations such as Namami Gange before being hit by the tariff hike. Despite mounting losses, he expressed support for the government's stance against US trade TO 10 LAKH JOBS Leather trader Javed Iqbal warned the tariff hike could devastate Kanpur and neighbouring Unnao, where the industry employs nearly 10 lakh people. Lower tariffs for Pakistan, China, Vietnam, and Cambodia are expected to draw away American buyers. 'We stand with the government, even if it means bearing heavy losses in the national interest,' he HALTED DESPITE FESTIVE ORDERSPrerna Verma, a leather accessories exporter, said confusion over the new policy has brought production to a near standstill. Demand in recent years has already fallen to 60% of previous levels, forcing some units to lay off Iraqi, Chairman of the Council for Leather Exports (Central Region), said that although Christmas orders have arrived, production for the US market has been halted. He met Commerce Minister Piyush Goyal in Delhi two to three days ago, where the government discussed possible relief measures—such as interest subsidies—in the case of a 25% tariff. However, with the import duty now set at 50%, such measures are unlikely to suffice. 'Buyers and sellers can manage an extra 5–10% cost but such a steep hike is beyond anyone's capacity," he said.- EndsTune InMust Watch
Time of India
an hour ago
- Time of India
Cohance to invest Rs 110 crore in new facilities in Hyderabad and New Jersey
Hyderabad: Cohance Lifesciences Limited, backed by PE giant Advent International, is investing Rs 110 crore in its facilities in Hyderabad and New Jersey. This includes $10 million (approx. Rs 87 crore) in expanding its cGMP bioconjugation capabilities at its US-based subsidiary, NJ Bio, and Rs 23 crore in its new cGMP oligonucleotide building block manufacturing facility in Hyderabad. The new facility in Hyderabad, Cohance said, will enable it to take high-value chemistries like modified nucleosides and locked nucleic acids (LNA) from laboratory scale to full commercial manufacturing to fulfil the needs of innovators advancing oligonucleotide-based therapeutics. The Hyderabad-based company mentioned that the Hyderabad plant, integrated with a pilot plant for early-stage synthesis and non-GMP scale-up, will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad | Gold Rates Today in Hyderabad | Silver Rates Today in Hyderabad The company said the US investment will significantly enhance its capabilities to deliver fully integrated antibody-drug conjugate (ADC) solutions. The strategic investment in Hyderabad will strengthen its integrated oligonucleotide platform and boost its prospects as a preferred partner for emerging modalities by enhancing its ability to support innovators from early development through late-phase clinical supply. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Once back of the pack, Chinese running shoes now look to surge ahead in S'pore market CNA Read More Undo The two investments are part of its planned capacity expansion programme across high-growth modalities, which would enhance its ability to serve global innovators from early development to commercial supply, the company said. Cohance Lifesciences Executive Chairman Vivek Sharma said: "Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics. " Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
